Islet cell therapy - Kadimastem

Drug Profile

Islet cell therapy - Kadimastem

Alternative Names: Beta cell therapy - Kadimastem; Encapsulin

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kadimastem
  • Class Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Israel (Implant)
  • 22 Apr 2018 Kadimastem entered into an agreement (memorandum of understanding) with Defymed to develop islet cell therapy in combination with encapsulation solution technology for Type-1 diabetes mellitus
  • 18 Aug 2016 Kadimastem and a medical device company signed an addendum for stem cell-based therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top